Stock Events

Merck & 

$127.53
8
-$1-0.78% Wednesday 16:29

Statistics

Day High
128.43
Day Low
126.9
52W High
116.13
52W Low
83.15
Volume
7,660.18
Avg. Volume
95,476
Mkt Cap
-
P/E Ratio
0.16
Dividend Yield
2.42%
Dividend
3.08

Upcoming

Dividends

2.42%Dividend Yield
Jan 24
$0.77
Oct 23
$0.73
Jul 23
$0.73
Apr 23
$0.73
Jan 23
$0.73

Earnings

25AprConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-2.17
-0.74
0.7
2.13
Expected EPS
2.04
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0QAH.LSE. It's not an investment recommendation.

About

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Show more...
CEO
Mr. Kenneth C. Frazier
Employees
73000
Country
US
ISIN
US58933Y1055
WKN
000A0YD8Q

Listings